New DELIVER guidelines aim to accelerate nanomedicine development

They’re tiny drug-delivery systems 1000 times smaller than a human hair, but while nanomedicines have long been hailed as the future for treating debilitating and life-threatening diseases, their journey from lab to patient has many challenges.

Intercept to sell in $800M cash buyout after second NASH rejection sank hopes

Intercept Pharmaceuticals plans to hand over its liver disease drug Ocaliva and other pipeline projects to Italian pharma Alfasigma in a $19 per-share cash deal

September 27, 2023

EMA approves Bavarian Nordic’s mpox vaccine for teenagers – Pharmaceutical Technology

Adolescents in Europe aged 12 to 17 years can now receive the vaccine. Image credit: Shutterstock / ZaitsevMaksym. The European Medicines Agency (EMA) has approved

September 20, 2024

Biotechs turn to gene silencing for obesity drugs that can last longer than Wegovy

Enticed by the immense market opened by GLP-1 weight loss drugs Wegovy and Zepbound, a handful of biotech companies are trying to develop next-generation, longer-lasting

May 23, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.